Skip to main content

Advertisement

Table 1 Baseline characteristics of the subjects

From: Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

  Febuxostat n = 105 Benzbromarone n = 109 P value
Age, years 52.42 ± 11.73 50.27 ± 14.15 0.23
Onset age, years 41.80 ± 10.57 43.19 ± 13.15 0.48
Height, cm 172.65 ± 5.65 172.39 ± 5.83 0.77
Body weight, kg 78.89 ± 9.49 77.27 ± 9.55 0.28
BMI, kg/m2 26.59 ± 3.03 26.10 ± 2.75 0.25
Waistline, cm 94.60 ± 7.41 92.31 ± 7.92 0.10
Waist-to-hip ratio 0.92 ± 0.05 0.92 ± 0.04 0.65
Systolic BP, mmHg 128.42 ± 13.55 126.78 ± 16.93 0.51
Diastolic BP, mmHg 83.47 ± 8.74 82.07 ± 9.67 0.32
Coexisting conditions
 Hypertension 25 (22.9) 20 (19.0) 0.33
 Cardiovascular disease 5 (4.6) 7 (6.7) 0.60
 Diabetes 7 (6.4) 3 (2.9) 0.30
 Hyperlipidemia 32 (29.4) 34 (32.4) 0.91
 Fatty liver 26 (23.9) 28 (26.7) 0.88
 Tophus 26 (23.9) 21 (20) 0.33
 Family history of gout 24 (22.0) 26 (24.8) 0.86
  1. Data given as mean ± SD or number (%). *P ≤ 0.05. **P ≤ 0.01. BMI body mass index, BP blood pressure